Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
LYRA Stock Chart & Stats
$3.64
>-$0.01(-3.42%)
At close: 4:00 PM EST
$3.64
>-$0.01(-3.42%)
Day’s Range― - ―
52-Week Range$2.84 - $37.50
Previous CloseN/A
Volume832.93K
Average Volume (3M)74.31K
Market Cap
$6.45M
Enterprise Value$20.86M
Total Cash (Recent Filing)$22.05M
Total Debt (Recent Filing)$31.38M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Mar 11, 2026EPS Estimate
-1.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.38
Shares Outstanding1,774,882
10 Day Avg. Volume44,319
30 Day Avg. Volume74,310
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)57.96
Price to Sales (P/S)438.05
P/FCF Ratio-9.29
Enterprise Value/Market Cap3.23
Enterprise Value/Revenue34.77
Enterprise Value/Gross Profit69.54
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$16.00Price Target Upside339.56% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-12.81
Revenue Forecast (FY)$533.33K
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignThe new Phase 3 study will include enhancements such as open label extension and independent review panels, aimed at improving the study's statistical power and accuracy.
Regulatory ProgressRegulatory feedback from the FDA has set a clear path towards a New Drug Application for chronic rhinosinusitis patients without nasal polyps.
Study OutcomesThe ENLIGHTEN 2 study met its primary and key secondary endpoints, renewing hope for LYR-210.
Bears Say
Financial NeedsThe company will need to raise cash to fund the study, and topline data is nearly two years away, leading to a Neutral rating.
Funding ChallengesManagement has indicated that the potential to start the trial is pending additional funding, which could delay progress.
Lyra Therapeutics News
LYRA FAQ
What was Lyra Therapeutics’s price range in the past 12 months?
Lyra Therapeutics lowest stock price was $2.84 and its highest was $37.50 in the past 12 months.
What is Lyra Therapeutics’s market cap?
Lyra Therapeutics’s market cap is $6.45M.
When is Lyra Therapeutics’s upcoming earnings report date?
Lyra Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 86 days.
How were Lyra Therapeutics’s earnings last quarter?
Lyra Therapeutics released its earnings results on Nov 12, 2025. The company reported -$3.38 earnings per share for the quarter, beating the consensus estimate of -$5.255 by $1.875.
Is Lyra Therapeutics overvalued?
According to Wall Street analysts Lyra Therapeutics’s price is currently Undervalued.
Does Lyra Therapeutics pay dividends?
Lyra Therapeutics does not currently pay dividends.
What is Lyra Therapeutics’s EPS estimate?
Lyra Therapeutics’s EPS estimate is -1.92.
How many shares outstanding does Lyra Therapeutics have?
Lyra Therapeutics has 1,774,882 shares outstanding.
What happened to Lyra Therapeutics’s price movement after its last earnings report?
Lyra Therapeutics reported an EPS of -$3.38 in its last earnings report, beating expectations of -$5.255. Following the earnings report the stock price went down -1.546%.
Which hedge fund is a major shareholder of Lyra Therapeutics?
Currently, no hedge funds are holding shares in LYRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lyra Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming the treatment of chronic respiratory diseases through innovative drug delivery solutions. The company specializes in developing therapies for patients suffering from conditions such as chronic rhinosinusitis and other nasal and sinus disorders using its proprietary LYR-210 and LYR-220 product candidates, which aim to provide sustained release of therapeutic agents directly to the affected areas.
LYRA Stock 12 Month Forecast
Average Price Target
$16.00
▲(339.56% Upside)
Technical Analysis
XTL Biopharmaceuticals Sponsored ADR
―
Mustang Bio
―
Bolt Biotherapeutics
―
TransCode Therapeutics
―
Silexion Therapeutics
―